Insiders · CALC

Daniel E. Geffken

Interim CFO at CalciMedica, Inc. (CALC) since March 2023

Daniel E. Geffken has filed 12 insider reports with the SEC since February 2021, as interim CFO at CalciMedica, Inc. (CALC), chief Financial Officer at Cero Therapeutics Holdings, Inc. (CERO) and officer at ProMIS Neurosciences Inc. (PMN) and at 2 more companies. Daniel E. Geffken made no open-market purchases or sales in the last 12 months. The latest filing, on May 20, 2024, reports grant or award at CalciMedica, Inc. (CALC).

Filings
12
Companies
5
Bought on market
$36K
Sold on market
None

Companies where Daniel E. Geffken is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
CalciMedica, Inc. logo
CALC
CalciMedica, Inc.
Interim CFOsince March 2023$1.22May 20, 2024
Cero Therapeutics Holdings, Inc. logo
CERO
Cero Therapeutics Holdings, Inc.
Chief Financial Officer10,002$0.0951Feb 17, 2024
ProMIS Neurosciences Inc. logo
PMN
ProMIS Neurosciences Inc.
Officer$3.21Oct 30, 2023
Windtree Therapeutics Inc /de/ logo
WINT
Windtree Therapeutics Inc /de/
Director2,175Aug 29, 2023
Eloxx Pharmaceuticals, Inc. logo
ELOX
Eloxx Pharmaceuticals, Inc.
Officersince April 202150,000$36K$0.72$11.74+1531%Dec 1, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Daniel E. Geffken.

Compare Daniel E. Geffken with

Other insiders at the same companies

Questions about Daniel E. Geffken

What is Daniel E. Geffken's role at CalciMedica, Inc.?
Daniel E. Geffken reports to the SEC as interim CFO at CalciMedica, Inc. (CALC), according to the latest filing on May 20, 2024. Daniel E. Geffken has also filed as chief Financial Officer at Cero Therapeutics Holdings, Inc. (CERO), officer at ProMIS Neurosciences Inc. (PMN), director at Windtree Therapeutics Inc /de/ (WINT) and officer at Eloxx Pharmaceuticals, Inc. (ELOX).
How many shares does Daniel E. Geffken own?
After the latest filing that states it, Daniel E. Geffken directly owned 10,002 shares of Cero Therapeutics Holdings, Inc. (CERO), 2,175 shares of Windtree Therapeutics Inc /de/ (WINT) and 50,000 shares of Eloxx Pharmaceuticals, Inc. (ELOX). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Daniel E. Geffken bought or sold stock recently?
The most recent open-market purchase was on November 29, 2021: bought 50,000 shares of Eloxx Pharmaceuticals, Inc. (ELOX) for $36K at an average of $0.72.
How do I get alerts when Daniel E. Geffken files?
Follow Daniel E. Geffken on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Daniel E. Geffken (SEC CIK 0001314756). Totals count each trade once, skipping amendments whose original is on file, from Feb 6, 2021 on. View on SEC EDGAR